EYPT Earnings & Financial Statements
EyePoint Pharmaceuticals, Inc.
$3.14
+$0.13(+4.32%)
31
Overall
40
Value
18
Tech
36
Quality
Market Cap
$259.50M
Volume
2.83M
52W Range
$3.05 - $19.11
Target Price
$26.10
EYPT earnings and financial statements: EyePoint Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
EYPT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $31.37M | $43.27M | $46.02M | $41.40M | $36.94M |
| Cost of revenue | $2.07M | $3.71M | $500.0K | $8.33M | - |
| Operating income | -$243.43M | -$145.85M | -$75.07M | -$99.64M | -$55.28M |
| EBITDA | -$229.34M | -$129.23M | -$69.00M | -$96.62M | -$28.83M |
| Net income | -$231.96M | -$130.87M | -$70.80M | -$102.25M | -$58.42M |
| EPS (diluted) | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $364.00M | $418.46M | $355.18M | $180.36M | $263.37M |
| Total liabilities | $57.88M | $81.96M | $88.86M | $83.99M | $78.99M |
| Shareholders’ equity | $306.11M | $336.50M | $266.32M | $96.37M | $184.38M |
| Cash and equivalents | $101.82M | $99.70M | $281.26M | $95.63M | $178.59M |
| Long-term debt | $20.77M | $21.86M | $4.91M | $35.29M | $38.42M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$240.11M | -$126.23M | $1.88M | -$65.00M | -$50.10M |
| Capital expenditure | -$3.13M | -$4.05M | -$3.48M | -$2.15M | -$156.0K |
| Free cash flow | -$243.39M | -$130.28M | -$1.61M | -$67.16M | -$50.25M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EYPT | $3.14 | +4.3% | 2.83M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get EyePoint Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW